Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.72 |
| ▸ | HRH1 | P35367 | 5/20 | 0.72 |
| ▸ | HRH2 | P25021 | 2/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.72 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877466 | 0.84 | HRH4 (1.00) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL20572670 | 0.81 | HRH4 (0.73) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL20572693 | 0.80 | HRH4 (0.70) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL3138898 | 0.78 | HRH4 (0.67) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL4874447 | 0.77 | HRH4 (0.86) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL3143960 | 0.77 | HRH4 (0.66) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL3138418 | 0.76 | HRH4 (0.65) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL4876969 | 0.76 | HRH4 (0.72) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL604800 | 0.74 | HRH4 (0.79) | HRH4HRH1HRH2HRH3 | |
| SCHEMBL3147608 | 0.72 | HRH4 (0.57) | HRH4HRH1HRH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546410-B2 | Heteroaryl-fused macrocyclic pyrimidine derivatives | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100004256-A1 | HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009137492-A1 | HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004256-A1 | HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES | CDK2, DPYD, CCNB1 | HRH4 1115/4885HRH1 832/4885HRH2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.